IPO
Karolinska Development AB has published its Annual Report for 2018.
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Monday, May 6, 2019 at 5pm ET to discuss first quarter 2019 financial results and provide a corporate update.
Auris Medical Holding Ltd. announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20.
Recipharm AB will publish its interim report for January-March 2019 on 3 May at 07:45 am CET.
Biom’up announced its full-year results for the year ending December 31, 2018, as approved by the Company’s Board of Directors on April 29, 2019, and provided an update on its operations.
Following the capital increase and listing on Nasdaq, cash and cash equivalents totaled €314.1 million as of March 31, 2019
Fusion Antibodies plc announces that Dr Paul Kerr, Chief Executive Officer of the Company, has purchased 1,290 ordinary shares in the Company at a price of 77 pence per Ordinary Share.
BioArctic AB to publish the company’s Interim Report for the period January – March 2019 on Thursday, May 9, 2019 at 08:00 a.m. CET.
Motif Bio plc announced that its notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company’s website at www.motifbio.com.
Karolinska Development AB announces that The Board of Directors has decided to delay the publication of its Annual Report for 2018.
PRESS RELEASES